Risperdal Drug Maker, Johnson & Johnson Inc. (J&J), is involved in legal action with regard to Risperdal Drug, once utilized in treating various psychiatric disorders including schizophrenia and bi-polar disorder. The lawsuit asserts that J&J not only failed to warn patients about potentially hazardous side effects but also that it illegally marketed the drug for unapproved uses.
Recent research now shows Risperdal increasing the risk of serious medical side effects, including but not limited to strokes, heart problems, diabetes, tardive dyskinesia (a disorder that involves involuntary movements), hyperglycemia (High Blood Sugar), hypersosmolar coma (Diabetic Coma), diabetes, and gynecomastia (a condition which causes abnormal growth in male breasts).
The United States Department of Justice began investigating Risperdal sales practices in 2004, and joined in a Qui Tam (whistleblowers) lawsuit in 2010. The case alleged the paying of bribes to a large pharmaceutical drug supplier to promote the drug’s use in nursing homes. The lawsuit alleged that tens of millions of dollars were paid to Omnicare physicians.
In November 2013, Janssen Pharmaceuticals, Inc., (JPI) of Titusville, N.J entered a guilty plea agreement and a $400 million fine for introducing a mis-branded drug into the marketplace. Jansseen (a J&J company) would have to pay an additional $1.67 BILLION in civil damages.
In 2012, J&J reported over 400 lawsuits filed against the company with regard to the Risperdal drug. Conservative estimates have the amount of plaintiffs increase by a factor of 10 by 2015 in both state and federal jurisdictions. Of the approximately 400, about 130 cases involve complications causing gynecomastia (male breast growth).